MGI Highlights Breakthrough WGS Pricing at VIB NGS Conference
Ghent, Belgium, 29 March 2023 – MGI Tech Co., Ltd. (“MGI”), a global leader in life science tools and technology, showcased its breakthrough whole genome sequencing (WGS) pricing at the 5th edition of Revolutionizing Next-Generation Sequencing (NGS), a VIB Tools & Technology conference held on 27-28 March in Ghent, Belgium. The company emphasized the cost-effectiveness of its DNBSEQ-T20×2* and DNBSEQ-T7* ultra-high throughput sequencing platforms.
Achieving the $100 Genome
The industry has long aimed to reduce genome sequencing costs to $100 or less per unit. At the AGBT General Meeting 2023, MGI achieved this milestone, launching the DNBSEQ-T20×2* with a WGS cost of under $100.
At the VIB conference, Dr. Yong Hou, General Manager of MGI Europe and Africa, presented “Trailblazing Path to Sub-Hundred-Dollar Genome” during Plenary Session 3: Outbreak & Population Scale, reiterating the significance of this pricing breakthrough and its accessibility in the European market.
“This milestone and the commercialization of DNBSEQ-T20×2* mark the beginning of the $100 genome era. Lower sequencing costs will accelerate the global expansion of genomics,” said Dr. Hou. “With our growing regional team, a Customer Experience Centre in Riga, and multiple lab facilities, MGI is ready to provide cutting-edge, affordable technologies to empower customers across Europe and Africa.”
The Power of DNBSEQ-T20×2*
Using MGI’s dip-immersion biochemistry, the DNBSEQ-T20×2* significantly improves sequencing efficiency, scalability, and cost-effectiveness. A single set of DNBSEQ-T20×2* can deliver up to 50,000 WGS per year, with a per-genome cost of under $100 (30x coverage, including instrument depreciation).
Key features:
- 6-slide capacity per run
- Up to 42Tb output per run (PE100)
- Up to 72Tb output per run (PE150)
- Open modular structure, replacing traditional closed biochemical liquid circuit systems
This revolutionary platform, with its unmatched single-machine throughput, is reshaping the future of genomic research.
“Our mission is to provide faster, cost-effective, and accurate sequencing solutions—whether for pathogen identification in a post-pandemic world or advancing precision medicine,” said Dr. Rade Drmanac, Chief Scientific Officer.
DNBSEQ-T7*: The $150 Genome
Dr. Hou also discussed MGI’s $150 per genome offering for its flagship DNBSEQ-T7*, achievable when running 15,000 WGS per year at 30x coverage.
The DNBSEQ-T7* is a highly flexible, production-scale sequencer that enables:
- Simultaneous but independent operation of up to 4 flow cells
- Support for single-cell RNA sequencing, whole exome sequencing, and whole genome sequencing within different flow cells
- 1-6T of high-quality data per day
- PE150 read length
Powered by DNBSEQ Technology, the DNBSEQ-T7* offers enhanced biochemical, fluidics, and optical systems, accelerating cost reductions and enabling large-scale projects in genomics, multi-omics, and spatial omics.
Disclaimers:
- Unless otherwise noted, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents, are not available in Germany, Spain, the UK, Sweden, Italy, Czech Republic, Switzerland, and Hong Kong (CoolMPS is available in Hong Kong).
- Products are for Research Use Only. Not for use in diagnostic procedures (except where explicitly stated).
